Clinical Trials Logo

Clinical Trial Summary

This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts:

1. Single Dose Period - will characterise the absorption, metabolism, excretion and pharmacokinetics of a single oral dose of [14C]AZD2014 from the body

2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour activity of multiple doses of AZD2014 when given as a monotherapy or given in combination with paclitaxel or fulvestrant.


Clinical Trial Description

This is a Phase I, open label, single centre, non-randomised study in patients with advanced solid malignancies that is refractory or resistant to standard treatment or where no suitable effective standard treatment exists or for whom paclitaxel or fulvestrant are appropriate treatment choices. The study will be divided in two parts:

1. Single Dose Period - will enrol up to 6 evaluable patients to characterise the absorption, metabolism, excretion and pharmacokinetics of a single radiolabelled [14C] oral dose of 125mg AZD2014 via residential intensive PK sampling over 8 days. An evaluable patient is defined as patient who does not vomit within 2 hours post dose and who has completed the scheduled PK sampling.

2. Multiple Dose Period - patients who have completed the Single Dose Period may continue to receive treatment as outpatients. Patients will be allocated to different treatment regimes as decided between Investigator and patient on a risk / benefit basis. From Day 1, Cycle 1, non-radiolabelled AZD2014 treatment will be administered as oral tablets to patients, either as:

i. 50mg BD monotherapy ii. 125mg BD taken on first 2 days of treatment each week in combination with 500mg intramuscular fulvestrant on Day 1, Cycle 1, Day 15, Cycle 1; Day 1, Cycle 2, then Day 1 of each monthly cycle thereafter iii. 50mg BD taken on first 3 days of treatment each week for 6 weeks in combination with a single weekly paclitaxel infusion (80mg/m2 ) followed by a one week break from treatment where no AZD2014 or paclitaxel will be given. This 7 week schedule composes one cycle of treatment. Patients will be given up to 6 cycles of paclitaxel, although additional cycles of paclitaxel may be given if deemed appropriate by the Investigator.

Radiolabelled AZD2014 will be administered to fasted patients (i.e. no food 2 hours before and 1 hour after each dose). Non-radiolabelled AZD2014 will be administered either under fasted or non-fasted conditions. The safety and tolerability and anti-tumour activity of AZD2014 and combination with paclitaxel or fulvestrant will be evaluated in all enrolled patients respectively using conventional safety parameters, AEs/SAEs and RECIST 1.1. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02640755
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date January 28, 2016
Completion date July 6, 2017

See also
  Status Clinical Trial Phase
Completed NCT01202370 - A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Completed NCT00162136 - Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. Phase 1
Recruiting NCT05006794 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Phase 1
Active, not recruiting NCT02537418 - Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens Phase 1
Completed NCT01540526 - Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Phase 1
Completed NCT00033202 - This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor Phase 1
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Completed NCT05866354 - To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Phase 1
Terminated NCT00695370 - Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children Phase 2
Completed NCT02325739 - FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression Phase 1/Phase 2
Completed NCT00676299 - A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. Phase 1
Active, not recruiting NCT00090727 - Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase 1
Terminated NCT01112397 - Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours Phase 1
Not yet recruiting NCT00751894 - Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) Phase 2